Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Binghe Xu, Min Yan et al.|BMJ|2023Cited by 82
Salidroside can target both P4HB-mediated inflammation and melanogenesis of the skinXiujuan Ding, Huijuan Liu, Yuyan Yang et al.|Theranostics|2020Cited by 59
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.Zefei Jiang, Hua Yang, Tao Sun et al.|Journal of Clinical Oncology|2022Cited by 36